Table 4.
HRs for Cardioembolic Stroke
| Group 1 No AF, No Comorbidities n=7837 (27.7%) | Group 2 No AF, Has Comorbidities n=18 103 (64.1%) | Group 3 Has AF, No Comorbidities n=386 (1.4%) | Group 4 Has AF, Has Comorbidities n=1927 (6.8%) | |
|---|---|---|---|---|
| Cardioembolic strokes | 23 | 165 | 9 | 86 |
| Cardioembolic stroke incidence rate (per 1000 person‐y) | 0.31 | 0.94 | 3.74 | 5.43 |
| Unadjusted HR | 1.0 (reference) | 3.40 (2.24–5.39) | 8.54 (3.75–17.85) | 18.38 (11.81–29.79) |
| Model 1 | 1.0 (reference) | 2.57 (1.64–4.25) | 4.77 (1.74–11.23) | 11.95 (7.26–19.68) |
| Model 2 | 1.0 (reference) | 2.38 (1.51–3.96) | 4.01 (1.33–9.94) | 11.02 (6.62–18.33) |
| Model 3 | 1.0 (reference) | 2.34 (1.48–3.90) | 3.12 (1.15–8.46) | 8.25 (4.79–14.21) |
Model 1 adjusts for age, sex, race, education, income, and geographic region. Model 2 adjusts for the covariates in model 1, with the addition of high‐density lipoprotein cholesterol, total cholesterol, body mass index, and smoking. Model 3 adjusts for the covariates in model 2, with the addition of regular aspirin use and warfarin use. Incidence rates and hazard ratios (HRs) specific to cardioembolic stroke for each group. The hazard for cardioembolic stroke remained elevated in group 3 after adjustment. AF indicates atrial fibrillation.